Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Abrocitinib · Cibinqo

Small molecule · Inhibitor of Janus kinase 1 (JAK1) · developed by Pfizer

Approved FDA, Jan 2022
PFE Developer
1 Registered trials

What is Abrocitinib?

Abrocitinib is an oral Janus kinase inhibitor that reversibly binds the ATP site of JAK1, showing selectivity over JAK2, JAK3 and TYK2. It is studied in eczema, and the label describes its use in refractory, moderate-to-severe atopic dermatitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Cibinqo, PF-04965842
Drug type
Small molecule
Targets
Janus kinase 1 (JAK1)
Mechanism
Inhibitor of Janus kinase 1 (JAK1)
Pathways
JAK-STAT signaling
Therapy area
Dermatology
Developer
Pfizer (PFE)
FDA status
Approved as Cibinqo (January 14, 2022), NDA213871 · FDA label
UNII
73SM5SF3OR

✅ FDA-approved uses

From the indications section of the FDA label (version of Sep 9, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06807268 Phase 3 Eczema Active not recruiting PFE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Eczema

Other drugs acting on JAK1

More from Pfizer

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the PFE page.

Follow PFE, the company behind Abrocitinib

See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PFE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.